ganirelix


Also found in: Wikipedia.

ganirelix

 [gan″ĭ-rel´iks]
a synthetic compound derived from, and an antagonist to, gonadotropin-releasing hormone; used as the acetate salt to inhibit premature luteinizing hormone (LH) surges in women undergoing ovarian hyperstimulation in the treatment of female infertility, administered subcutaneously.

ganirelix

(ga-ni-rell-ix) ,

Antagon

(trade name)

Classification

Therapeutic: hormones
Pregnancy Category: X

Indications

As a component of infertility regimens (with recombinant follicle stimulating hormone [FSH], and human chorionic gonadotropin) to inhibit premature luteinizing hormone (LH) surges in patients undergoing controlled ovarian hyperstimulation.

Action

Induces a rapid, reversible suppression of gonadotropin (FSH and LH) secretion, which suppresses surges in LH. Ganirelix is a gonadotropin-releasing hormone antagonist.

Therapeutic effects

Suppression of LH surges increases the implantation and pregnancy rates in patients undergoing in vitro fertilization.

Pharmacokinetics

Absorption: Well absorbed following subcutaneous administration.
Distribution: 44 L.
Metabolism and Excretion: Metabolized to two primary metabolites; 18% excreted unchanged in urine.
Half-life: 16 hr.

Time/action profile (blood levels)

ROUTEONSETPEAKDURATION
Subcutunknown1 hrunknown

Contraindications/Precautions

Contraindicated in: Hypersensitivity to ganirelix, gonadotropin releasing hormone or any of its analogs; Obstetric: Known or suspected pregnancy.
Use Cautiously in: None noted.

Adverse Reactions/Side Effects

Gastrointestinal

  • ovarian hyperstimulation syndrome (life-threatening)
  • abdominal pain
  • nausea

Genitourinary

  • pelvic pain
  • vaginal bleeding

Local

  • hypersensitivity reactions (life-threatening)
  • injection site reactions

Interactions

Drug-Drug interaction

Unknown.

Route/Dosage

Subcutaneous (Adults) 250 mcg once daily during the mid-to-late follicular phase of menstrual cycle after initiating FSH on day 2 or 3 of cycle. Treatment with ganirelix should be continue daily until day of administration of human chorionic gonadotropin (when adequate follicular response achieved).

Availability

Injection: 250 mcg/0.5 mL in prefilled syringes

Nursing implications

Nursing assessment

  • Assess patient for pregnancy prior to therapy. Therapy should not be initiated if patient is pregnant.
  • Lab Test Considerations: May cause elevated neutrophil counts and decreased hematocrit and total bilirubin concentrations.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)

Implementation

  • Subcutaneous: Administer via subcutaneous injection only.

Patient/Family Teaching

  • Instruct patient on correct technique for subcutaneous injection. Most convenient sites are in the abdomen around the navel and in the upper thigh.

Evaluation/Desired Outcomes

  • Successful in vitro fertilization procedure.

ganirelix

/gan·i·re·lix/ (gan″ĭ-rel´iks) a synthetic decapeptide derived from, and an antagonist to, gonadotropin-releasing hormone; used as the acetate salt in the treatment of female infertility.

ganirelix

a gonadotropin-releasing hormone antagonist.
indications It is used to inhibit premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation.
contraindications Pregnancy, lactation, latex allergy, and known hypersensitivity to this drug prohibit its use.
adverse effects Fetal death is a life-threatening consequence of this drug's use. Other adverse effects include headache, ovarian hyperstimulation syndrome, gynecological abdominal pain, nausea, and pain on injection. Common side effects include spotting and breakthrough bleeding.
References in periodicals archive ?
Treatment with the GnRH antagonist Ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial.
Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome.
First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin releasing hormone antagonist ganirelix (Org 37462) Hum Reprod.
1982) First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotropin-releasing hormone antagonist ganirelix (Org 37432).
It offers discounts for patients with documented financial need and a valid prescription for Follstim, or Ganirelix and Pregynl.
She starts taking Ganirelix so she doesn't ovulate prior to my doctor's retrieval of her eggs.
Ganirelix (Ganirelix) and cetrorelix (Cetrotide) are GnRH antagonists similar in structure to GNRH.
Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies.
Polycystic ovarian syndrome (PCOS) patients have a favorable response to ganirelix acetate during controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF)-embryo transfer (ET).
Pais-sede do Medicamento fabricante Classificacao Anvisa ACETATO DE CASPOFUNGINA EUA Entidade molecular nova 50mg po liof inj ACETATO DE CETRORELIX Suica Entidade molecular nova 0,25mg po liof inj ACETATO DE GANIRELIX Holanda Entidade molecular nova 0,5mg/ml sol inj AMOXICILINA 1.
Currently approved treatments for infertility: clomiphene citrate, follicle-stimulating hormones, human menopausal hormones, Schering-Plough's Ganirelix, Merck Serono's Ovidrel.
Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix.